Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tadalafil for Prevention of Recurrent Ischemic Priapism in Sickle Cell Disease (PIN)
NCT05142254Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Ischemic priapism comparing Tadalafil + Hydroxyurea with Placebo + Hydroxyurea (2 arms). Primary endpoint: Change in the recurrence rate of priapism at 1 year. Started Apr 2022; status: completed.
02
Drugs
tadalafil
03
Conditions
Ischemic priapism
Beyond the preview
Go deeper on NCT05142254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142254.